Ascendis Pharma A/S (ASND)
NASDAQ: ASND · Real-Time Price · USD
246.31
+1.83 (0.75%)
Apr 20, 2026, 1:44 PM EDT - Market open
Ascendis Pharma Revenue
In the year 2025, Ascendis Pharma had annual revenue of 720.13M EUR with 98.03% growth. Ascendis Pharma had revenue of 247.50M in the quarter ending December 31, 2025, with 42.31% growth.
Revenue (ttm)
720.13M EUR
Revenue Growth
+98.03%
P/S Ratio
n/a
Revenue / Employee
605,662 EUR
Employees
1,189
Market Cap
n/a
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 720.13M | 356.49M | 98.03% |
| Dec 31, 2024 | 363.64M | 96.92M | 36.34% |
| Dec 31, 2023 | 266.72M | 215.54M | 421.20% |
| Jan 1, 2023 | 51.17M | 43.40M | 557.93% |
| Dec 31, 2021 | 7.78M | 825.00K | 11.87% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Incyte | 5.14B |
| Jazz Pharmaceuticals | 4.27B |
| Genmab | 3.72B |
| BioMarin Pharmaceutical | 3.22B |
| Exelixis | 2.32B |
| Moderna | 1.94B |
| Madrigal Pharmaceuticals | 958.40M |
| Ionis Pharmaceuticals | 943.71M |
ASND News
- 5 hours ago - Ascendis Pharma Announces Commencement of Trading of its Ordinary Shares on Nasdaq - GlobeNewsWire
- 12 days ago - Ascendis Pharma to List Ordinary Shares Directly on Nasdaq - GlobeNewsWire
- 12 days ago - New Data from Week 52 of the Ongoing COACH Trial Showed that TransCon® hGH Accelerated TransCon® CNP's Benefits Beyond Linear Growth in Children with Achondroplasia - GlobeNewsWire
- 13 days ago - Ascendis Receives Orphan Drug Exclusivity and Launches YUVIWEL® (Navepegritide) in the United States - GlobeNewsWire
- 4 weeks ago - New InsiGHTS Trial of TransCon® hGH (Lonapegsomatropin) in Turner Syndrome Demonstrated Comparable Efficacy and Safety to Daily Somatropin at Week 52 - GlobeNewsWire
- 5 weeks ago - New Two-Year Data from Pivotal ApproaCH Trial Showing Durable Benefits of TransCon® CNP (Navepegritide) in Children with Achondroplasia Shared at ACMG 2026 - GlobeNewsWire
- 7 weeks ago - Ascendis Pharma to Participate in the TD Cowen 46th Annual Health Care Conference - GlobeNewsWire
- 7 weeks ago - Ascendis wins U.S. approval for therapy for children with dwarfism - Reuters